Mechanisms of different yin nourishing and kidney tonifying methods on osteoclastysis pathway in ovariectomized rats #br#

	#br#

doi:10.12307/2025.284

Abstract

Abstract:
BACKGROUND: Liuwei Dihuang Wan takes “three tonifying and three reducing effects” as its compatibility feature to nourish yin and tonify the kidneys, while Zuogui Wan takes “seeking yin in yang” as its compatibility feature to nourish yin and tonify the kidneys by promoting yang. Both of them belong to the same method of nourishing yin and tonifying the kidneys, and have better curative effects at the symptomatic and cellular molecular levels.
OBJECTIVE: To observe the effects of Liuwei Dihuang Wan and Zuogui Wan in bone metabolism, and to explore their mechanism of action in the osteoprotegerin (OPG)/receptor activator of nuclear factor-κB ligand (RANKL) osteoblastic pathway.
METHODS: Thirty-two Sprague-Dawley rats were randomized into model, Liuwei Dihuang Wan, Zuogui Wan, and sham operation group, with eight rats in each group. Osteoporosis models were prepared using removal of both ovaries in the first three groups. Starting at 30 days postoperatively, rats in the Liuwei Dihuang Wan group were gavaged with Liuwei Dihuang Wan 1.125 g/kg/d; rats in the Zuoqui Wan group were gavaged with Zuogui Wan 2.25 g/kg/d; and rats in the sham operation group and the model group were gavaged with saline 10 mL/kg/d. After 12 weeks of gavage, the rat tibia was taken to measure bone mineral density. The serum levels of estrogen, bone alkaline phosphatase, and cAMP/cGMP were measured using ELISA, and the expression of OPG/RANKL in the femur was detected using western blot.
RESULTS AND CONCLUSION: Compared with the sham operation group, the model group showed a decrease in bone mineral density and levels of estrogen and bone alkaline phosphatase (P < 0.05) and an increase in cAMP/cGMP level (P < 0.05). Compared with the model group, the Liuwei Dihuang Wan group and the Zuogui Wan group significantly increased bone mineral density (P < 0.05) and bone alkaline phosphatase levels (P < 0.05); the Zuogui Wan group significantly decreased cAMP/cGMP levels (P < 0.05) and upregulated OPG expression (P < 0.05); the Liuwei Dihuang Wan group upregulated OPG expression and downregulated RANKL expression (P < 0.05); and both groups were unable to significantly increase estrogen levels (P > 0.05). To conclude, Zuogui Wan, which seeks yin from yang, can effectively increase the expression of OPG but cannot downregulate the expression of RANKL. However, Liuwei Dihuang Wan, which has three tonifying and three reducing effects, can bidirectionally regulate the expression of OPG and RANKL. This result suggests that Liuwei Dihuang Wan can significantly inhibit osteoclastic function compared with Zuogui Wan, and further research is needed to verify this conclusion.

Key words: postmenopausal osteoporosis, kidney yin deficiency syndrome, Liuwei Dihuang Wan, Zuogui Wan, bone protection, OPG, RANKL, western blot

CLC Number:

Huang Xiaobin, Ge Jirong, Li Shengqiang, Xie Lihua, Huang Jingwen, He Yanyan, Xue Lipeng. Mechanisms of different yin nourishing and kidney tonifying methods on osteoclastysis pathway in ovariectomized rats #br#

#br#

[J]. Chinese Journal of Tissue Engineering Research, 2025, 29(6): 1214-1219.

Figures/Tables 5

References

[1] 中华医学会骨质疏松和骨矿盐疾病分会,章振林.原发性骨质疏松症诊疗指南(2022)[J].中国全科医学,2023,26(14):1671-1691.
[2] 黄翌,李陈,王悦.中国人口老龄化进程及其经济动因的区域差异[J].地域研究与开发,2023,42(5):167-173.
[3] 葛继荣,王和鸣,郑洪新,等.中医药防治原发性骨质疏松症专家共识(2020)[J].中国骨质疏松杂志,2020,26(12):1717-1725.
[4] 卢勇,史亮,高振,等.经典中医古方治疗骨质疏松症的系统评价[J].中国组织工程研究与临床康复,2011,15(33):6247-6251.
[5] 匡浩铭,杨张琪,彭志飞,等.六味地黄丸治疗绝经后骨质疏松症疗效和安全性的Meta分析[J].中医正骨,2022,34(8):31-35+58.
[6] 牟宏亮,吴小燕,昝强,等.左归丸治疗骨质疏松症的临床应用及实验研究进展[J].中医学报,2021,36(4):763-768.
[7] YOUSEFZADEH N, KASHFI K, JEDDI S, et al. Ovariectomized Rat Model of Osteoporosis: A Practical Guide. EXCLI J. 2020;19:89-107.
[8] 夏炳江,童培建,孙燕,等.骨质疏松肾阴虚型小鼠病证结合模型建立的实验研究[J].中国中医急症,2013,22(7):1083-1086.
[9] FERBEBOUH M, VALLIÈRES F, BENDERDOUR M, et al. The pathophysiology of immunoporosis: innovative therapeutic targets.Inflamm Res. 2021;70(8):859-875.
[10] 谢希,高曦,娄宏君,等.骨质疏松症的骨免疫机制及中药单体干预研究[J].中医学报,2023,38(12):2590-2597.
[11] 王琦.中医理论现代化的定义、框架与内涵[J].中医杂志,2024, 65(1):6-12.
[12] 卢晓,于灵芝,周聪颖,等.常用实验动物全身性麻醉药物的使用[J].实验动物与比较医学,2022,42(1):18-25.
[13] 胡雄飞,陈志莲,袁姝.戊巴比妥钠与水合氯醛对大鼠麻醉效果的Meta分析[J].毒理学杂志,2020,34(3):208-213.
[14] 薛晓娟,刘彩,王益民,等.新时代中医药发展现状与思考[J].中国工程科学,2023,25 (5):11-20.
[15] 王常松,杨敏,闵莉,等.中医证研究面临的困境及对策[J].中华中医药杂志,2012,27(9):2365-2368.
[16] 魏凤琴,王小平,张安玲,等.中医现代化应走自主发展的道路——张珍玉学术思想研究[J].山东中医杂志,2016,35(10):851-853.
[17] 田力欣,赵天易,何丽云,等.《黄帝内经》“同病异治”再认识[J].中国中医基础医学杂志,2023,29(9):1416-1420.
[18] 李金霞,周小青,赖丽娜,等.“同证异治”内涵析辨[J].中国中医基础医学杂志,2021,27(12):1868-1870.
[19] 张慧康,于淼,周计春.六味地黄丸“三泻”药辨疑[J].中国中医基础医学杂志,2022,28(2):281.
[20] 钱乙.小儿药证直诀[M].北京:人民卫生出版社,2006:44.
[21] 金连峰,顾炜,刘子闻,等.基于TLR4/MyD88/NF-κB信号通路探讨左归丸、右归丸影响骨关节炎模型的作用机制研究[J].中华中医药学刊,2023,41(11):28-33+265.
[22] 朱化珍,陈晨,陶剑青,等.左归丸“阳中求阴”之数据挖掘[J].中医学报,2019,34(6):1348-1351.
[23] 秦臻,任艳玲.基于“阳为气、阴为味”探讨左归丸、右归丸的组方特点[J].中医杂志,2017,58(7):545-547+551.
[24] 刘艳艳,唐杨,林昌松,等.左归丸及其拆方治疗肾阴虚证的疗效分析探讨“阳中求阴”的临床意义[J].中华中医药学刊,2016,34(10): 2321-2323.
[25] MENGJ, ZHANGW, WANGC, et al. Catalpol suppresses osteoclastogenesis and attenuates osteoclast-derived bone resorption by modulating PTEN activity. Biochempharmacol. 2020;171:113715.
[26] QUINN JM, SALEH H. Modulation of osteoclast function in bone bythe immune system. Mol Cell Endocrinol. 2009;310(1-2):40-51.
[27] 刘强.OPG-RANKL-RANK信号通路——绝经后骨质疏松症的重要作用机制[J].中华骨科杂志,2021,41(10):668-674.
[28] 胡阳,宋敏,李凯,等.左归丸及其组方治疗绝经后骨质疏松症的基础研究进展[J].中华中医药学刊,2023,41(12):86-89.
[29] 彭渝淞,彭聪聪,单博文,等.六味地黄丸及组分治疗绝经后骨质疏松症概况[J].大众科技,2021,23(8):74-77+61.
[30] 李玉星.基于OPG和RANKL探讨六味地黄汤及其“补泻”药对干预绝经后骨质疏松模型大鼠的作用及其机制[D].长沙:湖南中医药大学,2018.
[31] 袁丽丽,刘梅洁,陶黎,等.“成骨-破骨”细胞阴阳理论阐释及意义[J].中国中医基础医学杂志,2019,25(6):733-734+771.
[32] 凌家艳,薛莎.薛莎基于“阳化气,阴成形”治疗绝经后骨质疏松症经验[J].中医药导报,2023,29(4):186-188+192.